Interest of the natriuretic peptides in veterinary cardiology

Los péptidos natriuréticos son una familia de hormonas que juegan un papel primario en la regulación de la homeostasis cardiovascular y renal. Tres han sido identificados, el péptido natriurético atrial (ANP), péptido natriurético tipo B (BNP) y péptido natriurético tipo C (CNP). ANP y BNP se sintetizan en el tejido cardíaco atrial y ventricular, respectivamente. En humanos, su concentración se relaciona con enfermedades cardíacas, renales, hipertensión, edad y sexo. Del mismo modo, en caninos y felinos, sus niveles se asocian con distintas patologías cardíacas, renales, hipertensión, obesidad. Actualmente, en animales de compañía, se consideran una herramienta complementaria en el diagnóstico, tratamiento y seguimiento de las cardiopatías. El presente trabajo tiene como objetivo llevar a cabo una revisión bibliográfica sobre los péptidos natriuréticos con la finalidad de poner en discusión sus perspectivas y aplicaciones en el campo de la cardiología veterinaria.The natriuretic peptides are a family of hormones that play a primary role in the regulation of the cardiovascular and renal homeostasis. Three have been identified: the atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP) and C type natriuretic peptide (CNP). The ANP and BNP are synthesized in the atrial and the ventricular cardiac tissue, respectively. In humans, they were related with cardiac and renal disease, hypertension, age and sex. In the same way, in canines and felines were also related with different cardiac pathologies, renal disease, hypertension, obesity . At present, they are considered a complementary tool in the diagnosis, treatment and prognosis in companion animal’s patients with cardiac disease. The objective of the present work was to carried out a bibliographic review among the actual natriuretic peptides available in the field of veterinary cardiology.Facultad de Ciencias Veterinaria

Interest of the natriuretic peptides in veterinary cardiology

Los péptidos natriuréticos son una familia de hormonas que juegan un papel primario en la regulación de la homeostasis cardiovascular y renal. Tres han sido identificados, el péptido natriurético atrial (ANP), péptido natriurético tipo B (BNP) y péptido natriurético tipo C (CNP). ANP y BNP se sintetizan en el tejido cardíaco atrial y ventricular, respectivamente. En humanos, su concentración se relaciona con enfermedades cardíacas, renales, hipertensión, edad y sexo. Del mismo modo, en caninos y felinos, sus niveles se asocian con distintas patologías cardíacas, renales, hipertensión, obesidad. Actualmente, en animales de compañía, se consideran una herramienta complementaria en el diagnóstico, tratamiento y seguimiento de las cardiopatías. El presente trabajo tiene como objetivo llevar a cabo una revisión bibliográfica sobre los péptidos natriuréticos con la finalidad de poner en discusión sus perspectivas y aplicaciones en el campo de la cardiología veterinaria.The natriuretic peptides are a family of hormones that play a primary role in the regulation of the cardiovascular and renal homeostasis. Three have been identified: the atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP) and C type natriuretic peptide (CNP). The ANP and BNP are synthesized in the atrial and the ventricular cardiac tissue, respectively. In humans, they were related with cardiac and renal disease, hypertension, age and sex. In the same way, in canines and felines were also related with different cardiac pathologies, renal disease, hypertension, obesity . At present, they are considered a complementary tool in the diagnosis, treatment and prognosis in companion animal’s patients with cardiac disease. The objective of the present work was to carried out a bibliographic review among the actual natriuretic peptides available in the field of veterinary cardiology.Facultad de Ciencias Veterinaria

Interest of the natriuretic peptides in veterinary cardiology

Los péptidos natriuréticos son una familia de hormonas que juegan un papel primario en la regulación de la homeostasis cardiovascular y renal. Tres han sido identificados, el péptido natriurético atrial (ANP), péptido natriurético tipo B (BNP) y péptido natriurético tipo C (CNP). ANP y BNP se sintetizan en el tejido cardíaco atrial y ventricular, respectivamente. En humanos, su concentración se relaciona con enfermedades cardíacas, renales, hipertensión, edad y sexo. Del mismo modo, en caninos y felinos, sus niveles se asocian con distintas patologías cardíacas, renales, hipertensión, obesidad. Actualmente, en animales de compañía, se consideran una herramienta complementaria en el diagnóstico, tratamiento y seguimiento de las cardiopatías. El presente trabajo tiene como objetivo llevar a cabo una revisión bibliográfica sobre los péptidos natriuréticos con la finalidad de poner en discusión sus perspectivas y aplicaciones en el campo de la cardiología veterinaria.The natriuretic peptides are a family of hormones that play a primary role in the regulation of the cardiovascular and renal homeostasis. Three have been identified: the atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP) and C type natriuretic peptide (CNP). The ANP and BNP are synthesized in the atrial and the ventricular cardiac tissue, respectively. In humans, they were related with cardiac and renal disease, hypertension, age and sex. In the same way, in canines and felines were also related with different cardiac pathologies, renal disease, hypertension, obesity . At present, they are considered a complementary tool in the diagnosis, treatment and prognosis in companion animal’s patients with cardiac disease. The objective of the present work was to carried out a bibliographic review among the actual natriuretic peptides available in the field of veterinary cardiology.Facultad de Ciencias Veterinaria

Lymphatic filariasis epidemiology in Samoa in 2018: geographic clustering and higher antigen prevalence in older age groups

Background: Samoa conducted eight nationwide rounds of mass drug administration (MDA) for lymphatic filariasis (LF) between 1999 and 2011, and two targeted rounds in 2015 and 2017 in North West Upolu (NWU), one of three evaluation units (EUs). Transmission Assessment Surveys (TAS) were conducted in 2013 (failed in NWU) and 2017 (all three EUs failed). In 2018, Samoa was the first in the world to distribute nationwide triple-drug MDA using ivermectin, diethylcarbamazine, and albendazole. Surveillance and Monitoring to Eliminate LF and Scabies from Samoa (SaMELFS Samoa) is an operational research program designed to evaluate the effectiveness of triple-drug MDA on LF transmission and scabies prevalence in Samoa, and to compare the usefulness of different indicators of LF transmission. This paper reports results from the 2018 baseline survey and aims to i) investigate antigen (Ag) prevalence and spatial epidemiology, including geographic clustering; ii) compare Ag prevalence between two different age groups (5–9 years versus ≥10 years) as indicators of areas of ongoing transmission; and iii) assess the prevalence of limb lymphedema in those aged ≥15 years. Methods: A community-based cluster survey was conducted in 30 randomly selected and five purposively selected clusters (primary sampling units, PSUs), each comprising one or two villages. Participants were recruited through household surveys (age ≥5 years) and convenience surveys (age 5–9 years). Alere Filariasis Test Strips (FTS) were used to detect Ag, and prevalence was adjusted for survey design and standardized for age and gender. Adjusted Ag prevalence was estimated for each age group (5–9, ≥10, and all ages ≥5 years) for random and purposive PSUs, and by region. Intraclass correlation (ICC) was used to quantify clustering at regions, PSUs, and households. Results: A total of 3940 persons were included (1942 children aged 5–9 years, 1998 persons aged ≥10 years). Adjusted Ag prevalence in all ages ≥5 years in randomly and purposively selected PSUs were 4.0% (95% CI 2.8–5.6%) and 10.0% (95% CI 7.4–13.4%), respectively. In random PSUs, Ag prevalence was lower in those aged 5–9 years (1.3%, 95% CI 0.8–2.1%) than ≥10 years (4.7%, 95% CI 3.1–7.0%), and poorly correlated at the PSU level (R-square = 0.1459). Adjusted Ag prevalence in PSUs ranged from 0% to 10.3% (95% CI 5.9–17.6%) in randomly selected and 3.8% (95% CI 1.3–10.8%) to 20.0% (95% CI 15.3–25.8%) in purposively selected PSUs. ICC for Ag-positive individuals was higher at households (0.46) compared to PSUs (0.18) and regions (0.01). Conclusions: Our study confirmed ongoing transmission of LF in Samoa, in accordance with the 2017 TAS results. Ag prevalence varied significantly between PSUs, and there was poor correlation between prevalence in 5–9 year-olds and older ages, who had threefold higher prevalence. Sampling older age groups would provide more accurate estimates of overall prevalence, and be more sensitive for identifying residual hotspots. Higher prevalence in purposively selected PSUs shows local knowledge can help identify at least some hotspots

Descripción de tres protocolos anestésicos fijos en cerdas sometidas a trasferencia embrionaria quirúrgica

La utilización del cerdo como modelo en investigación biomédica ha dado lugar a múltiples descripciones de protocolos anestésicos. El presente trabajo tiene por objeto socializar las dosis y drogas utilizadas en tres protocolos. Las tres cerdas anestesiadas, una por protocolo, son parte de la puesta a punto de la técnica de transferencia embrionaria quirúrgica. Protocolo 1: Medicación preanestésica: ketamina 15 mg/kg vía intramuscular, xilacina 3 mg/kg intramuscular. Inducción: midazolam 0,15 mg/kg vía EV. Mantenimiento: xilacina 0,6 mg/kg EV, y ketamina 3 mg/kg EV + dos refuerzos de ketamina 2 mg/kg EV. Protocolo 2: Medicación preanestésica: ketamina 15 mg/kg vía intramuscular, xilacina 3 mg/kg intramuscular. Inducción: midazolam 0,14 mg/kg vía endovenosa. Mantenimiento por vía endovenosa: Ketamina 1,5 mg/kg, Xilacina 0,6 mg/kg, Ketamina 2 mg/kg. Protocolo 3: Medicación preanestésica: ketamina 15 mg/kg vía intramuscular, xilacina 3 mg/kg intramuscular. Inducción: ketamina 5 mg/kg vía endovenosa. Mantenimiento por vía endovenosa: Xilacina 0,6 mg/kg, Ketamina 3 mg/kg, Ketamina 2 mg/kg, Ketamina 2 mg/kg. El planteo farmacológico del protocolo 3 requirió mayor frecuencia y dosis de drogas utilizada

Measurement of Semileptonic Branching Fractions of B Mesons to Narrow D** States

Using the data accumulated in 2002-2004 with the DO detector in proton-antiproton collisions at the Fermilab Tevatron collider with centre-of-mass energy 1.96 TeV, the branching fractions of the decays B -> \bar{D}_1^0(2420) \mu^+ \nu_\mu X and B -> \bar{D}_2^{*0}(2460) \mu^+ \nu_\mu X and their ratio have been measured: BR(\bar{b}->B) \cdot BR(B-> \bar{D}_1^0 \mu^+ \nu_\mu X) \cdot BR(\bar{D}_1^0 -> D*- pi+) = (0.087+-0.007(stat)+-0.014(syst))%; BR(\bar{b}->B)\cdot BR(B->D_2^{*0} \mu^+ \nu_\mu X) \cdot BR(\bar{D}_2^{*0} -> D*- \pi^+) = (0.035+-0.007(stat)+-0.008(syst))%; and (BR(B -> \bar{D}_2^{*0} \mu^+ \nu_\mu X)BR(D2*0->D*- pi+)) / (BR(B -> \bar{D}_1^{0} \mu^+ \nu_\mu X)\cdot BR(\bar{D}_1^{0}->D*- \pi^+)) = 0.39+-0.09(stat)+-0.12(syst), where the charge conjugated states are always implied.Comment: submitted to Phys. Rev. Let

Measurement of the Lifetime Difference in the B_s^0 System

We present a study of the decay B_s^0 -> J/psi phi We obtain the CP-odd fraction in the final state at time zero, R_perp = 0.16 +/- 0.10 (stat) +/- 0.02 (syst), the average lifetime of the (B_s, B_sbar) system, tau (B_s^0) =1.39^{+0.13}_{-0.16} (stat) ^{+0.01}_{-0.02} (syst) ps, and the relative width difference between the heavy and light mass eigenstates, Delta Gamma/Gamma = (Gamma_L - Gamma_H)/Gamma =0.24^{+0.28}_{-0.38} (stat) ^{+0.03}_{-0.04} (syst). With the additional constraint from the world average of the B_s^0$lifetime measurements using semileptonic decays, we find tau (B_s^0)= 1.39 +/- 0.06 ~ps and Delta Gamma/\Gamma = 0.25^{+0.14}_{-0.15}. For the ratio of the B_s^0 and B^0 lifetimes we obtain tau(B_s^0)/tau(B^0)} = 0.91 +/- 0.09 (stat) +/- 0.003 (syst).Comment: submitted to Phys. Rev. Lett. FERMILAB-PUB-05-324-